Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
11 04 2023
11 04 2023
Historique:
received:
13
04
2022
accepted:
13
10
2022
medline:
12
4
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same More than 1,600 patient-years of follow-up (>700 patients) were studied from 6 real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children's Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51, or 53, or other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-m walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for nongenotypic prognostic factors. These findings suggest the viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multigenotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in this study.
Sections du résumé
BACKGROUND AND OBJECTIVES
Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same
METHODS
More than 1,600 patient-years of follow-up (>700 patients) were studied from 6 real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children's Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51, or 53, or other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-m walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors.
RESULTS
The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for nongenotypic prognostic factors.
DISCUSSION
These findings suggest the viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multigenotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in this study.
Identifiants
pubmed: 36725339
pii: WNL.0000000000201626
doi: 10.1212/WNL.0000000000201626
pmc: PMC10103111
doi:
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1540-e1554Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Clin Med. 2019 May 10;8(5):
pubmed: 31083420
Can J Neurol Sci. 2016 Jan;43(1):163-77
pubmed: 26786644
Hum Mutat. 2015 Apr;36(4):395-402
pubmed: 25604253
Neurology. 2018 Jun 12;90(24):e2146-e2154
pubmed: 29752304
PLoS One. 2016 Sep 20;11(9):e0162542
pubmed: 27649492
Muscle Nerve. 2022 Jan;65(1):67-74
pubmed: 34606104
Hum Mutat. 2009 Mar;30(3):293-9
pubmed: 19156838
Neuromuscul Disord. 2022 Apr;32(4):271-283
pubmed: 35396092
Orphanet J Rare Dis. 2021 Apr 28;16(1):188
pubmed: 33910603
JAMA Neurol. 2020 Aug 1;77(8):982-991
pubmed: 32453377
Ann Neurol. 2015 Apr;77(4):684-96
pubmed: 25641372
Lancet Neurol. 2018 Mar;17(3):251-267
pubmed: 29395989
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1360-1372
pubmed: 35083887
Lancet Neurol. 2018 May;17(5):445-455
pubmed: 29398641
Trials. 2019 Sep 18;20(1):572
pubmed: 31533793
Muscle Nerve. 2021 Sep;64(3):285-292
pubmed: 34105177
J Hum Genet. 2017 Apr;62(4):459-463
pubmed: 27974813
PLoS One. 2021 Jun 25;16(6):e0253882
pubmed: 34170974
Mol Ther. 2010 Jun;18(6):1218-23
pubmed: 20332768
Nat Rev Dis Primers. 2021 Feb 18;7(1):13
pubmed: 33602943
Lancet. 2017 Sep 23;390(10101):1489-1498
pubmed: 28728956
Biometrics. 1988 Dec;44(4):1049-60
pubmed: 3233245
PLoS One. 2019 Jul 31;14(7):e0220714
pubmed: 31365579
Lancet Neurol. 2018 Apr;17(4):347-361
pubmed: 29395990
Muscle Nerve. 2006 Aug;34(2):135-44
pubmed: 16770791
Neuromuscul Disord. 2009 Jul;19(7):458-61
pubmed: 19553120
Neurology. 2016 Jul 26;87(4):401-9
pubmed: 27343068
Hum Mutat. 2018 Sep;39(9):1193-1202
pubmed: 29907980
Neurology. 2020 Sep 8;95(10):e1381-e1391
pubmed: 32611643
Ann Neurol. 2016 Feb;79(2):257-71
pubmed: 26573217
PLoS One. 2016 Oct 13;11(10):e0164684
pubmed: 27737016
Muscle Nerve. 2013 Sep;48(3):343-56
pubmed: 23681930
Muscle Nerve. 2020 Jan;61(1):36-43
pubmed: 31573675
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):149-55
pubmed: 25733532
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):
pubmed: 34074727
Nat Rev Drug Discov. 2019 Oct;18(10):797-807
pubmed: 31462747
PLoS One. 2019 Jun 25;14(6):e0218683
pubmed: 31237898
PLoS One. 2020 Jun 18;15(6):e0232870
pubmed: 32555695
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Drugs Today (Barc). 2021 Dec;57(12):707-717
pubmed: 34909800
Physiother Res Int. 2012 Jun;17(2):101-9
pubmed: 21954141
Nucleic Acid Ther. 2022 Feb;32(1):29-39
pubmed: 34788571
Neurology. 2020 May 26;94(21):e2270-e2282
pubmed: 32139505